MKI67 and neoplasm: In addition, we observed an increase in the expression of cytotoxicity (PRF1, GNLY, GZMB) and proliferation (MKI67) markers in the CD8+ T cells in PI3K/mTORi+PD‐1i‐treated tumours (Figure S4A).